ワークショップ9 EGFR遺伝子変異陽性肺癌に対する治療戦略

[WS9-1] Amivantamab plus lazertinib vs osimertinib in advanced NSCLC EGFR with biomarkers of high-risk

^○野上 尚之¹, Enriqueta Felip², Byoung Chul Cho³, Vanesa Gutierrez⁴, Adlinda Alip⁵, Benjamin Besse⁶, Shun Lu⁷, Alexander I. Spira⁸, Nicolas Girard⁹, Raffaele Califano¹⁰, Shirish M Gadgeel¹¹, James Chih-Hsin Yang¹², Koichi Azuma¹³, Joshua C Curtin¹⁴, Jiarui Zhang¹⁴, Anesh Panchal¹⁵, Mariah Ennis¹⁴, Seema Sethi¹⁴, Joshua M. Bauml¹⁴, Se-Hoon Lee¹⁶ (1.愛媛大学大学院医学系研究科地域胸部疾患治療学, 2.Universitat Autonoma de Barcelona, Barcelona, Spain, 3.Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, 4.Hospital Regional Universitario de Malaga y Virgen de la Victoria, IBIMA, Malaga, Spain, 5.University of Malaya, Kuala Lumpur, Malaysia, 6.Paris-Saclay University, Gustave Roussy, Villejuif, France, 7.Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China, 8.Virginia Cancer Specialists, Fairfax, VA, USA, 9.Universite de Versailles Saint-Quentin-en-Yvelines, Versailles, France, 10.The University of Manchester, Manchester, UK, 11.Henry Ford Cancer Institute, Detroit, MI, USA, 12.National Taiwan University Hospital, Taipei, Taiwan, 13.Kurume University School of Medicine, Kurume, Japan, 14.Janssen Research ＆ Development, Spring House, PA, USA, 15.Janssen Research ＆ Development, High Wycombe, UK, 16.Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea)

アンコール演題